58 results
8-K
EX-99.1
CRVS
Corvus Pharmaceuticals Inc
6 May 24
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
4:01pm
to certain ownership limitations, and the common warrants expire on June 30, 2025.
Business Update and Strategy
Prioritized Program: Soquelitinib
424B5
CRVS
Corvus Pharmaceuticals Inc
3 May 24
Prospectus supplement for primary offering
4:05pm
candidates, if approved;
our commercialization, marketing and manufacturing capabilities and strategy;
the pricing and reimbursement of our product … into this prospectus supplement, including our Annual Report on Form 10-K.
Overview
We are a clinical stage biopharmaceutical company. Our strategy
8-K
EX-99.1
3k6qjh3z dbzgq
19 Mar 24
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:02pm
8-K
EX-99.1
3o6ria ee34n5k
7 Nov 23
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
4:03pm
8-K
EX-99.1
bbuel
8 Aug 23
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
4:01pm
8-K
EX-99.1
42gva0v7ym6b
8 May 23
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
4:01pm
8-K
EX-99.1
9xr4yaep3b2xcteb
3 Nov 22
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
d6p znnfg9xkuysifr
8 Aug 22
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
nwa 3wv5ehcr
5 May 22
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
12:00am